Article Text

Download PDFPDF
Is adjuvant chemotherapy for non-small cell lung cancer here to stay?
  1. T J Warke
  1. Consultant Respiratory Physician, Royal Victoria Hospital, Belfast, UK;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In this study patients with completely resected stage IB or stage II non-small cell lung cancer were randomised to either adjuvant chemotherapy with vinorelbine and cisplatin (n = 242) or to observation (n = 240). The primary end point was overall median survival which was significantly prolonged in the chemotherapy group (94 v 73 …

View Full Text